Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

Condition:   SARS-CoV-2 Interventions:   Biological: Biological: mRNA-1273: 50 mcg;   Other: Placebo;   Biological: Biological: mRNA-1273: 100 mcg Sponsors:   ModernaTX, Inc.;   Biomedical Advanced Research and Development Authority Recruiting

Source: ClinicalTrials.gov - May 28, 2020 Category: Research Source Type: clinical trials